The immune contexture in cancer prognosis and treatment

By W. Fridman, L. Zitvogel, C. Sautès-Fridman, Guido Kroemer. Nature Reviews Clinical Oncology, 2017

1,945 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Tumor-infiltrating lymphocytes in the immunotherapy era (2020, background): “These results might be explained by the technical difficulties surrounding Treg cell quantification, the inability to detect multiple relevant markers at the same time, and the concomitant infiltration of other immune cells such as CD8 TILs.(50)”
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion (2018, background): “(232, 273)], taking into account that it may evolve and modify throughout the anticancer therapy (Figure 3).”
Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front (2019, background): “The iTME is a dynamic system in which the combination of immune CT, location, and functional orientation leads to a tumorrejecting or tumor-promoting environment (Chen and Mellman, 2017; Fridman et al., 2017).”
Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”